Is Molecular Mimicry Between Hpf4 and SARS-CoV-2 Spike Protein a Potential Basis for Autoimmune Responses in Vaccinated and Naturally Infected Patients?

Vaccination against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) will hopefully terminate the pandemic of coronavirus disease 2019 (COVID-19) and sev-eral vaccines are now available. The Medical Agency has approved four vaccines 1 for the prevention of symptomatic COVID-19: two messenger RNA (mRNA) – based vaccines (mRNA BNT162b2-BioNTech/P fi zer and mRNA-1273-Moderna) encoding the spike protein antigen of SARS-CoV-2 and two recombinant adenoviral vector – based vaccines (ChAdOx1-AstraZeneca and Ad26.COV2.S -Janssen) encoding the spike glycoprotein of SARS-CoV-2. thrombosis) moder-ate-to-severe thrombocytopeniawere